Altfest L J & Co. Inc. Decreases Stock Holdings in Boston Scientific Corporation $BSX

Altfest L J & Co. Inc. lowered its holdings in Boston Scientific Corporation (NYSE:BSX) by 31.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,562 shares of the medical equipment provider’s stock after selling 5,840 shares during the period. Altfest L J & Co. Inc.’s holdings in Boston Scientific were worth $1,226,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC lifted its stake in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. Axiom Investors LLC DE raised its holdings in shares of Boston Scientific by 26.8% during the 1st quarter. Axiom Investors LLC DE now owns 4,759,258 shares of the medical equipment provider’s stock valued at $480,114,000 after buying an additional 1,006,828 shares during the period. Aprio Wealth Management LLC acquired a new position in Boston Scientific during the 1st quarter worth approximately $201,000. Ancora Advisors LLC boosted its holdings in Boston Scientific by 14.2% in the 1st quarter. Ancora Advisors LLC now owns 3,622 shares of the medical equipment provider’s stock worth $365,000 after acquiring an additional 450 shares during the period. Finally, Advisors Asset Management Inc. grew its position in Boston Scientific by 5.5% in the first quarter. Advisors Asset Management Inc. now owns 35,833 shares of the medical equipment provider’s stock valued at $3,615,000 after acquiring an additional 1,863 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $94.72 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The firm’s 50-day simple moving average is $97.92 and its 200-day simple moving average is $100.92. The firm has a market cap of $140.42 billion, a PE ratio of 50.65, a price-to-earnings-growth ratio of 1.69 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period in the previous year, the company earned $0.63 earnings per share. Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 93,095 shares of company stock worth $9,305,450. 0.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

BSX has been the topic of a number of recent research reports. The Goldman Sachs Group reissued a “buy” rating and set a $124.00 target price on shares of Boston Scientific in a research report on Wednesday, October 22nd. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Canaccord Genuity Group decreased their price objective on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Robert W. Baird lifted their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Finally, Royal Bank Of Canada increased their price target on Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average target price of $124.85.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.